Table 1.
Disease characteristics in RA patients.
| RA Patients (n = 73) | |
|---|---|
| Sex female | 66 (90%) |
| Disease duration (years) | 14.5 ± 9.7 |
| VAS (mm) | 52.5 ± 24.7 |
| Global assessment (mm) | 46.5 ± 23.9 |
| Tender joints | 3 ± 3.9 |
| Swollen joints | 2.7 ± 3.4 |
| DAS28 | 3.7 ± 1.2 |
| HAQ | 1.3 ± 0.9 |
| ESR (mm/h) | 22 ± 15.6 |
| Anti-CCP (UA/mL) † | 48.8 ± 90.5 |
| RF (mg/dL) ‡ | 241.6 ± 449.3 |
| DMARDs Methotrexate Leflunomide Sulfasalazine Hydroxychloroquine |
64 (88%) 21 (29%) 4 (6%) 1 (1%) |
| Prednisolone | 72 (99%) |
Results are expressed as number (percentage), mean ± SD, as appropriate. † Anti-CCP measurements were only available for 71 patients (97%). ‡ RF measurements were only available for 72 patients (99%). VAS, visual analogue scale; DAS28, disease activity score in 28 joints; HAQ, Health Assessment Questionnaire; ESR, erythrocyte sedimentation rate; anti-CCP, anti-cyclic citrullinated peptide; RF, rheumatoid factor; DMARDs, disease modifying anti-rheumatic drugs.